Your browser doesn't support javascript.
loading
N-Substituted piperazine-coupled imidazo[2,1-b]thiazoles as inhibitors of Mycobacterium tuberculosis: Synthesis, evaluation, and docking studies.
Chirra, Nagaraju; Abburi, Naga Pranathi; Rekha, Estharla Madhu; Pedapati, Ravi Kumar; Bollikanda, Rakesh Kumar; Murahari, Manikanta; Sriram, Dharmarajan; Sridhar, Balasubramanian; Kantevari, Srinivas.
Afiliação
  • Chirra N; Fluoro & Agrochemicals Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, Telangana, India.
  • Abburi NP; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India.
  • Rekha EM; Fluoro & Agrochemicals Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, Telangana, India.
  • Pedapati RK; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India.
  • Bollikanda RK; Medicinal Chemistry and Antimycobacterial Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science-Pilani, Hyderabad, Telangana, India.
  • Murahari M; Fluoro & Agrochemicals Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, Telangana, India.
  • Sriram D; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India.
  • Sridhar B; Fluoro & Agrochemicals Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, Telangana, India.
  • Kantevari S; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India.
Drug Dev Res ; 85(1): e22153, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38349258
ABSTRACT
An innovative series of N-substituted piperazine-linked imidazothiazole derivatives 7(a-x) were synthesized, and their antitubercular effectiveness was evaluated. A three-step reaction sequence involving the condensation of 1,3-dichloroacetone and thiourea, coupling with substituted piperazines to give the intermediates 5(a-d) and cyclization with substituted α-bromoacetophenones produced the desired imidazothiazole derivatives 7(a-x) in excellent yields. In vitro screening of new derivatives against Mycobacterium tuberculosis H37Rv resulted in 7k (minimum inhibitory concentration [MIC] 0.78 µg/mL) and 7g and 7h (MIC 1.56 µg/mL) as potent hit compounds. Further, the docking studies of the promising compounds 7k, 7g, and 7h revealed that the best molecular interactions are with the DprE1 in complex with sulfonyl PBTZ of M. tuberculosis as the target protein (PDB ID 6G83).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mycobacterium tuberculosis Idioma: En Revista: Drug Dev Res Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mycobacterium tuberculosis Idioma: En Revista: Drug Dev Res Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Índia